Electrochemotherapy (ECT) has emerged as an effective local treatment for cancer in dogs and cats. This technique consists of the transient and reversible permeabilization of cell membranes through the application of an electric field. The transient permeabilization increases the uptake of hydrophilic chemotherapeutic agents (bleomycin, cisplatin) into tumor cells, thereby enhancing their cytotoxic effect. ECT is primarily indicated for cutaneous and subcutaneous tumors of various histological types, including squamous cell carcinomas, mast cell tumors, and soft tissue sarcomas. It is also applied to tumors located in the oral cavity, sinonasal region, urinary bladder, and perianal area. ECT may be used as monotherapy, in the surgical bed following tumor excision, or as an adjuvant therapy when complete surgical margins are not achievable. Additionally, it can be employed as a neoadjuvant treatment, followed by surgical resection. Adverse effects are predominantly local and transient, including erythema, edema, pain, and necrosis. Thus, toxicity is generally mild, with most patients exhibiting good tolerance. For optimal outcomes, individualized follow-up is essential to assess therapeutic response, monitor adverse effects, and detect potential tumor recurrence. The aim of this review is to present the principles for the use of the technique in small animal clinical practice, including its indications, clinical applications, contraindications, adverse effects, and follow-up.
MagliettiF, TelladoM, De RobertisM, et al.Electroporation as the immunotherapy strategy for cancer in veterinary medicine: State of the art in Latin America. Vaccines (Basel), 2020; 8(3):537; doi: 10.3390/vaccines8030537
2.
MilovancevM, RussellDS. Surgical margins in the veterinary cancer patient. Vet Comp Oncol, 2017; 15(4):1136–1157; doi: 10.1111/vco.12284
3.
YeomSC, SongKH, SeoKW. The application of electrochemotherapy in three dogs with inoperable cancers. Korean J Vet Res, 2021; 61(1):e9; doi: 10.14405/kjvr.2021.61.e9
4.
Martins TaquesM, GuedertR, MorenoK, et al.Adjuvant electrochemotherapy after debulking in canine bone osteosarcoma infiltration. Artif Organs, 2021; 45(3):309–315; doi: 10.1111/aor.13820
5.
SpugniniEP, BaldiA. Electrochemotherapy in veterinary oncology. Vet Clin North Am Small Anim Pract, 2019; 49(5):967–979; doi: 10.1016/j.cvsm.2019.04.006
6.
GehlJ. Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand, 2003; 177(4):437–447; doi: 10.1046/j.1365-201X.2003.01093.x
7.
GeboersB, SchefferHJ, GraybillPM, et al.High-Voltage electrical pulses in oncology: Irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology, 2020; 295(2):254–272; doi: 10.1148/radiol.2020192190
8.
Malyško-PtašinskėV, StaigvilaG, NovickijV. Invasive and non-invasive electrodes for successful drug and gene delivery in electroporation-based treatments. Front Bioeng Biotechnol, 2022; 10:1094968; doi: 10.3389/fbioe.2022.1094968
9.
KotnikT, RemsL, TarekM, et al.Membrane electroporation and electropermeabilization: Mechanisms and models. Annu Rev Biophys, 2019; 48(1):63–91; doi: 10.1146/annurev-biophys-052118-115451
10.
YarmushML, GolbergA, SeršaG, et al.Electroporation-Based technologies for medicine: Principles, applications, and challenges. Annu Rev Biomed Eng, 2014; 16(1):295–320; doi: 10.1146/annurev-bioeng-071813-104622
11.
MiklavcicD, DavalosRV. Electrochemotherapy (ECT) and Irreversible Electroporation (IRE) -advanced techniques for treating deep-seated tumors based on electroporation. Biomed Eng Online, 2015; 14(Suppl 3):I1; doi: 10.1186/1475-925X-14-S3-I1
12.
DavalosRV, MirLM, RubinskyB. Tissue ablation with irreversible electroporation. Ann Biomed Eng, 2005; 33(2):223–231; doi: 10.1007/s10439-005-8981-8
13.
RaiZL, FeakinsR, PallettLJ, et al.Irreversible Electroporation (IRE) in locally advanced pancreatic cancer: A review of current clinical outcomes, mechanism of action and opportunities for synergistic therapy. J Clin Med, 2021; 10(8):1609; doi: 10.3390/jcm10081609
14.
DeipolyiAR, GolbergA, YarmushML, et al.Irreversible electroporation: The evolution of a laboratory technique to be used in interventional oncology. Diagn Interv Radiol, 2014; doi: 10.5152/dir.2013.13304
15.
MiklavčičD, MaliB, KosB, et al.Electrochemotherapy: From the drawing board into medical practice. Biomed Eng Online, 2014; 13(1):29; doi: 10.1186/1475-925X-13-29
16.
CvetkoskaA, PircE, RebersekM, et al.Towards standardization of electroporation devices and protocols. IEEE Instrum Meas Mag, 2020; 23(2):74–81; doi: 10.1109/MIM.2020.9062692
17.
GothelfA, MirLM, GehlJ. Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev, 2003; 29(5):371–387; doi: 10.1016/S0305-7372(03)00073-2
18.
LopesLB, PintarelliGB, GuedertR, et al.Novel tetrapolar single-needle electrode for electrochemotherapy in bone cavities: Modeling, design and validation. Med Eng Phys, 2024; 125:104120; doi: 10.1016/j.medengphy.2024.104120
19.
EsmaeiliN, FriebeM. Electrochemotherapy: A review of current status, alternative IGP approaches, and future perspectives. J Healthc Eng, 2019; 2019:2784516–2784511; doi: 10.1155/2019/2784516
20.
SersaG, MiklavcicD, CemazarM, et al.Electrochemotherapy in treatment of tumours. Eur J Surg Oncol, 2008; 34(2):232–240; doi: 10.1016/j.ejso.2007.05.016
21.
IvorraA, Al-SakereB, RubinskyB, et al.Use of conductive gels for electric field homogenization increases the antitumor efficacy of electroporation therapies. Phys Med Biol, 2008; 53(22):6605–6618; doi: 10.1088/0031-9155/53/22/020
22.
TozonN, Lampreht TratarU, ZnidarK, et al.Operating procedures of the electrochemotherapy for treatment of tumor in dogs and cats. J Vis Exp, 2016(116):54760; doi: 10.3791/54760
23.
MirLM, GehlJ, SersaG, et al.Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer, 2006; 4(11):14–25; doi: 10.1016/j.ejcsup.2006.08.003
24.
PircE, MiklavčičD, UršičK, et al.High-Frequency and high-voltage asymmetric bipolar pulse generator for electroporation based technologies and therapies. Electronics, 2021; 10(10):1203; doi: 10.3390/electronics10101203
25.
FuscoR, Di BernardoE, D’AlessioV, et al.Reduction of muscle contraction and pain in electroporation-based treatments: An overview. World J Clin Oncol, 2021; 12(5):367–381; doi: 10.5306/wjco.v12.i5.367
26.
MiklavcicD, CorovicS, PuciharG, et al.Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. Eur J Cancer, 2006; 4(11):45–51; doi: 10.1016/j.ejcsup.2006.08.006
27.
AndradeDLLS, GuedertR, PintarelliGB, et al.Electrochemotherapy treatment safety under parallel needle deflection. Sci Rep, 2022; 12(1):2766; doi: 10.1038/s41598-022-06747-x
28.
BigiL, GaldoG, CesinaroAM, et al.Electrochemotherapy induces apoptotic death in melanoma metastases: A histologic and immunohistochemical investigation. Clin Cosmet Investig Dermatol, 2016; 9:451–459; doi: 10.2147/CCID.S115984
29.
HadzialjevicB, OmerzelM, TrotovsekB, et al.Electrochemotherapy combined with immunotherapy – a promising potential in the treatment of cancer. Front Immunol, 2023; 14:1336866; doi: 10.3389/fimmu.2023.1336866
30.
JarmT, CemazarM, MiklavcicD, et al.Antivascular effects of electrochemotherapy: Implications in treatment of bleeding metastases. Expert Rev Anticancer Ther, 2010; 10(5):729–746; doi: 10.1586/era.10.43
31.
MuirT, BertinoG, GroseljA, et al.Bleomycin Electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report. Radiol Oncol, 2023; 57(2):141–149; doi: 10.2478/raon-2023-0029
32.
OttlakanA, LazarG, OlahJ, et al.Current updates in bleomycin-based electrochemotherapy for deep-seated soft-tissue tumors. Electrochem, 2023; 4(2):282–290; doi: 10.3390/electrochem4020019
33.
CemazarM, ParkinsCS, HolderAL, et al.Electroporation of human microvascular endothelial cells: Evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer, 2001; 84(4):565–570; doi: 10.1054/bjoc.2000.1625
34.
SersaG, JarmT, KotnikT, et al.Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer, 2008; 98(2):388–398; doi: 10.1038/sj.bjc.6604168
35.
BendixMB, HoustonA, FordePF, et al.Electrochemotherapy and immune interactions; A boost to the system? Eur J Surg Oncol, 2022; 48(9):1895–1900; doi: 10.1016/j.ejso.2022.05.023
CalvetCY, FaminD, AndréFM, et al.Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology, 2014; 3(4):e28131; doi: 10.4161/onci.28131
38.
KesarU, MarkelcB, JesenkoT, et al.Effects of electrochemotherapy on immunologically important modifications in tumor cells. Vaccines (Basel), 2023; 11(5):925; doi: 10.3390/vaccines11050925
39.
FalkH, LambaaS, JohannesenHH, et al.Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma – a case report. Acta Oncol, 2017; 56(8):1126–1131; doi: 10.1080/0284186X.2017.1290274
40.
OrlowskiS, BelehradekJ, PaolettiC, et al.Transient electropermeabilization of cells in culture. Biochem Pharmacol, 1988; 37(24):4727–4733; doi: 10.1016/0006-2952(88)90344-9
41.
SersaG, CemazarM, MiklavcicD. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res, 1995; 55(15):3450–3455.
42.
IshidaS, LeeJ, ThieleDJ, et al.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A, 2002; 99(22):14298–14302; doi: 10.1073/pnas.162491399
43.
GhoshS. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019; 88:102925; doi: 10.1016/j.bioorg.2019.102925
44.
YimitA, AdebaliO, SancarA, et al.Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. Nat Commun, 2019; 10(1):309; doi: 10.1038/s41467-019-08290-2
45.
MathewsMS, BlickenstaffJW, ShihE-C, et al.Photochemical internalization of bleomycin for glioma treatment. J Biomed Opt, 2012; 17(5):058001; doi: 10.1117/1.JBO.17.5.058001
46.
TounektiO, PronG, BelehradekJ, et al.Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res, 1993; 53(22):5462–5469.
47.
CalvetCY, MirLM. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev, 2016; 35(2):165–177; doi: 10.1007/s10555-016-9615-3
48.
GehlJ, SersaG, MatthiessenLW, et al.Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol, 2018; 57(7):874–882; doi: 10.1080/0284186X.2018.1454602
49.
RangelMMM, LinharesLCM, de OliveiraKD, et al.Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs. Sci Rep, 2023; 13(1):21078; doi: 10.1038/s41598-023-45433-4
50.
TelladoM, MirLM, MagliettiF. Veterinary guidelines for electrochemotherapy of superficial tumors. Front Vet Sci, 2022; 9:868989; doi: 10.3389/fvets.2022.868989
51.
CampanaLG, MiklavčičD, BertinoG, et al.Electrochemotherapy of superficial tumors – Current status. Semin Oncol, 2019; 46(2):173–191; doi: 10.1053/j.seminoncol.2019.04.002
52.
MagliettiF, TelladoM, OlaizN, et al.Combined local and systemic bleomycin administration in electrochemotherapy to reduce the number of treatment sessions. Radiol Oncol, 2016; 50(1):58–63; doi: 10.1515/raon-2016-0015
53.
TamzaliY, BordeL, RolsMP, et al.Successful treatment of equine sarcoids with cisplatin electrochemotherapy: A retrospective study of 48 cases. Equine Vet J, 2012; 44(2):214–220; doi: 10.1111/j.2042-3306.2011.00425.x
54.
GiardinoR, FiniM, BonazziV, et al.Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. Biomed Pharmacother, 2006; 60(8):458–462; doi: 10.1016/j.biopha.2006.07.016
55.
TelladoMN, MagliettiFH, MichinskiSD, et al.Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome. Radiol Oncol, 2020; 54(1):68–78; doi: 10.2478/raon-2020-0014
56.
SuzukiDOH, BerkenbrockJA, de OliveiraKD, et al.Novel application for electrochemotherapy: Immersion of nasal cavity in dog. Artif Organs, 2017; 41(8):767–773; doi: 10.1111/aor.12858
57.
BertinoG, MuirT, OdiliJ, et al.Treatment of basal cell carcinoma with electrochemotherapy: Insights from the InspECT registry (2008–2019). Curr Oncol, 2022; 29(8):5324–5337; doi: 10.3390/curroncol29080423
58.
TorrigianiF, PieriniA, LoweR, et al.Soft tissue sarcoma in dogs: A treatment review and a novel approach using electrochemotherapy in a case series. Vet Comp Oncol, 2019; 17(3):234–241; doi: 10.1111/vco.12462
59.
MozzilloN, CaracòC, MoriS, et al.Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med, 2012; 10(1):131; doi: 10.1186/1479-5876-10-131
60.
de Castro CunhaRM, LavalleGE, NunesFC, et al.Canine squamous cell carcinoma: Electrochemotherapy association with surgery and correlation with overall survival. Vet Comp Oncol, 2023; 21(2):240–254; doi: 10.1111/vco.12882
61.
Dos AnjosDS, BuenoC, MagalhãesLF, et al.Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma. Sci Rep, 2019; 9(1):15819; doi: 10.1038/s41598-019-52461-6
62.
dos SantosFFQ, LinharesLCM, RochaMdCP, et al.Perineural invasion as a predictor of local recurrence in cats with squamous cell carcinoma treated with electrochemotherapy. Front Vet Sci, 2024; 11:1408260; doi: 10.3389/fvets.2024.1408260
63.
Dos AnjosDS, SierraOR, SpugniniEP, et al.Comparison of two different doses of bleomycin in electrochemotherapy protocols for feline cutaneous squamous cell carcinoma nonsegregated from ultraviolet light exposure. Sci Rep, 2020; 10(1):18362; doi: 10.1038/s41598-020-75472-0
64.
Ferrer-JordaE, Rodríguez-PizàI. Description of outcome and adverse events in 21 cats with locally advanced nasal planum squamous cell carcinoma treated with electrochemotherapy. J Feline Med Surg, 2024; 26(7):1098612X241248043; doi: 10.1177/1098612X241248043
65.
SimčičP, PieriniA, LubasG, et al.A retrospective multicentric study of electrochemotherapy in the treatment of feline nasal planum squamous cell carcinoma. Vet Sci, 2021; 8(3):53; doi: 10.3390/vetsci8030053
66.
TelladoM, MichinskiS, ImpellizeriJ, et al.Electrochemotherapy using thin-needle electrode improves recovery in feline nasal planum squamous cell carcinoma - a translational model. Cancer Drug Resist, 2022; 5(3):595–611; doi: 10.20517/cdr.2022.24
67.
SpugniniEP, VincenziB, CitroG, et al.Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas. In Vivo, 2007; 21(5):819–822.
68.
SpugniniEP, VincenziB, AmadioB, et al.Adjuvant electrochemotherapy with bleomycin and cisplatin combination for canine soft tissue sarcomas: A study of 30 cases. Open Vet J, 2019; 9(1):88–93; doi: 10.4314/ovj.v9i1.15
69.
SpugniniEP, BaldiA, VincenziB, et al.Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: A preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol, 2007; 59(3):375–381; doi: 10.1007/s00280-006-0281-y
70.
SpugniniEP, RenaudSM, BuglioniS, et al.Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: An approach to improve the therapeutic index of highly toxic chemotherapy drugs. J Transl Med, 2011; 9(1):152; doi: 10.1186/1479-5876-9-152
71.
SpugniniEP, VincenziB, CarocciF, et al.Combination of bleomycin and cisplatin as adjuvant electrochemotherapy protocol for the treatment of incompletely excised feline injection-site sarcomas: A retrospective study. Open Vet J, 2020; 10(3):267–271; doi: 10.4314/ovj.v10i3.4
72.
KodreV, CemazarM, PecarJ, et al.Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo, 2009; 23(1):55–62.
73.
SpugniniEP, VincenziB, CitroG, et al.Evaluation of cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. J Vet Intern Med, 2011; 25(2):407–411; doi: 10.1111/j.1939-1676.2011.0678.x
74.
SpugniniEP, VincenziB, BaldiF, et al.Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res, 2006; 26(6B):4585–4589.
75.
MagliettiF, TelladoM, OlaizN, et al.Minimally invasive electrochemotherapy procedure for treating nasal duct tumors in dogs using a single needle electrode. Radiol Oncol, 2017; 51(4):422–430; doi: 10.1515/raon-2017-0043
76.
SpugniniEP, DragonettiE, VincenziB, et al.Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma. Melanoma Res, 2006; 16(1):23–27; doi: 10.1097/01.cmr.0000195702.73192.a0
77.
SimčičP, LoweR, GranzieraV, et al.Electrochemotherapy in treatment of canine oral non‐tonsillar squamous cell carcinoma. A case series report. Vet Comp Oncol, 2020; 18(3):428–432; doi: 10.1111/vco.12530
78.
TozonN, KodreV, SersaG, et al.Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res, 2005; 25(2A):839–845.
79.
TozonN, KodreV, JuntesP, et al.Electrochemotherapy is highly effective for the treatment of canine perianal hepatoid adenoma and epithelioma. Acta Vet (Beogr), 2010; 60(2–3):285–302; doi: 10.2298/AVB1003285T
80.
GasymovaE, MeierV, GuscettiF, et al.Retrospective clinical study on outcome in cats with nasal planum squamous cell carcinoma treated with an accelerated radiation protocol. BMC Vet Res, 2017; 13(1):86; doi: 10.1186/s12917-017-1018-3
81.
dos SantosA, LamegoÉC, EisenhardtLM, et al.Prevalence and anatomopathological characterization of cutaneous squamous cell carcinomas with regional and distant metastases in dogs and cats: 20 cases (1985–2020). Vet Comp Oncol, 2023; 21(2):291–301; doi: 10.1111/vco.12887
82.
WillcoxJL, MarksSL, UedaY, et al.Clinical features and outcome of dermal squamous cell carcinoma in 193 dogs (1987-2017). Vet Comp Oncol, 2019; 17(2):130–138; doi: 10.1111/vco.12461
83.
MurphyS. Cutaneous squamous cell carcinoma in the cat. J Feline Med Surg, 2013; 15(5):401–407; doi: 10.1177/1098612X13483238
84.
TozonN, PavlinD, SersaG, et al.Electrochemotherapy with intravenous bleomycin injection: An observational study in superficial squamous cell carcinoma in cats. J Feline Med Surg, 2014; 16(4):291–299; doi: 10.1177/1098612X13507071
85.
GagnonJ, MayerMN, BelosowskyT, et al.Stereotactic body radiation therapy for treatment of soft tissue sarcomas in 35 dogs. J Am Vet Med Assoc, 2020; 256(1):102–110; doi: 10.2460/javma.256.1.102
86.
Sanchez‐RedondoS, HareCHZ, Constantino‐CasasF, et al.Correlation between cytologic features and histologic grades in cutaneous and subcutaneous soft tissue sarcomas in dogs—A pilot study. Vet Clin Pathol, 2021; 50(2):236–239; doi: 10.1111/vcp.12975
87.
ZajcAL, HarperA, BenoitJ, et al.Non-injection-site soft tissue sarcoma in cats: Outcome following adjuvant radiotherapy. J Feline Med Surg, 2022; 24(8):e183–e193; doi: 10.1177/1098612X221098961
88.
CrownshawAH, McEnteeMC, NolanMW, et al.Evaluation of variables associated with outcomes in 41 dogs with incompletely excised high-grade soft tissue sarcomas treated with definitive-intent radiation therapy with or without chemotherapy. J Am Vet Med Assoc, 2020; 256(7):783–791; doi: 10.2460/javma.256.7.783
89.
DobromylskyjM. Feline soft tissue sarcomas: A review of the classification and histological grading, with comparison to human and canine. Animals (Basel), 2022; 12(20):2736; doi: 10.3390/ani12202736
90.
HartmannK, DayMJ, ThiryE, et al.; European Advisory Board on Cat Diseases. Feline injection-site sarcoma. J Feline Med Surg, 2015; 17(7):606–613; doi: 10.1177/1098612X15588451
91.
MirL, DevauchelleP, Quintin-ColonnaF, et al.First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br J Cancer, 1997; 76(12):1617–1622; doi: 10.1038/bjc.1997.606
92.
WelleMM, BleyCR, HowardJ, et al.Canine mast cell tumours: A review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol, 2008; 19(6):321–339; doi: 10.1111/j.1365-3164.2008.00694.x
93.
SabattiniS, ScarpaF, BerlatoD, et al.Histologic grading of canine mast cell tumor. Vet Pathol, 2015; 52(1):70–73; doi: 10.1177/0300985814521638
94.
de NardiAB, dos Santos HortaR, Fonseca-AlvesCE, et al.Diagnosis, prognosis and treatment of canine cutaneous and subcutaneous mast cell tumors. Cells, 2022; 11(4):618; doi: 10.3390/cells11040618
95.
OliveiraMT, CamposM, LamegoL, et al.Canine and feline cutaneous mast cell tumor: A comprehensive review of treatments and outcomes. Top Companion Anim Med, 2020; 41:100472; doi: 10.1016/j.tcam.2020.100472
96.
MortierJR, BlackwoodL. Treatment of nasal tumours in dogs: A review. J Small Anim Pract, 2020; 61(7):404–415; doi: 10.1111/jsap.13173
97.
NolanMW, BermanAR, Watson-SkaggsML, et al.Stereotactic radiotherapy (10 Gy X 3) for canine nonlymphomatous intranasal tumors is associated with prolonged survival and minimal risk of severe radiotoxicity. J Am Vet Med Assoc, 2022; 260(12):1496–1506; doi: 10.2460/javma.22.03.0141
98.
RassnickKM, GoldkampCE, ErbHN, et al.Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993–2003). J Am Vet Med Assoc, 2006; 229(3):401–406; doi: 10.2460/javma.229.3.401
99.
FulkersonCM, KnappDW. Management of transitional cell carcinoma of the urinary bladder in dogs: A review. Vet J, 2015; 205(2):217–225; doi: 10.1016/j.tvjl.2015.01.017
100.
KimS, HosoyaK, TakagiS, et al.Outcomes following balloon dilation for management of urethral obstruction secondary to urothelial carcinoma in dogs: 12 cases (2010–2015). J Am Vet Med Assoc, 2019; 255(3):330–335; doi: 10.2460/javma.255.3.330
101.
GhisoniG, FogliaA, SabattiniS, et al.A retrospective clinico-pathologic study of 35 dogs with urethral transitional cell carcinoma undergoing treatment. Animals (Basel), 2023; 13(14):2395; doi: 10.3390/ani13142395
102.
McMillanSK, KnappDW, Ramos-VaraJA, et al.Outcome of urethral stent placement for management of urethral obstruction secondary to transitional cell carcinoma in dogs: 19 cases (2007–2010). J Am Vet Med Assoc, 2012; 241(12):1627–1632; doi: 10.2460/javma.241.12.1627
103.
Dos AnjosDS, BuosiRG, RorattoI, et al.Preliminary assessment of electrochemotherapy feasibility in dogs with vesical transitional cell carcinoma. Vet Res Forum, 2020; 11(3):289–293; doi: 10.30466/vrf.2020.113009.2688
104.
CrayM, SelmicLE, RupleA. Demographics of dogs and cats with oral tumors presenting to teaching hospitals: 1996–2017. J Vet Sci, 2020; 21(5):e70; doi: 10.4142/jvs.2020.21.e70
105.
Castejón-GonzálezAC, ReiterAM. Oral and maxillofacial tumor management - from biopsy to surgical removal. Vet Clin North Am Small Anim Pract, 2022; 52(1):235–270; doi: 10.1016/j.cvsm.2021.09.005
106.
van der SteenF, ZandvlietM. Treatment of canine oral papillary squamous cell carcinoma using definitive‐intent radiation as a monotherapy—a case series. Vet Comp Oncol, 2021; 19(1):152–159; doi: 10.1111/vco.12646
107.
BostonSE, van SteeLL, BaconNJ, et al.Outcomes of eight cats with oral neoplasia treated with radical mandibulectomy. Vet Surg, 2020; 49(1):222–232; doi: 10.1111/vsu.13341
108.
NemecA, MilevojN, Lampreht TratarU, et al.Electroporation-based treatments in small animal veterinary oral and maxillofacial oncology. Front Vet Sci, 2020; 7:575911; doi: 10.3389/fvets.2020.575911
109.
GarciaJS, NowoshV, LópezRVM, et al.Association of systemic inflammatory and immune indices with survival in canine patients with oral melanoma, treated with experimental immunotherapy alone or experimental immunotherapy plus metronomic chemotherapy. Front Vet Sci, 2022; 9:888411; doi: 10.3389/fvets.2022.888411
110.
SpugniniEP, PorrelloA. Potentiation of chemotherapy in companion animals with spontaneous large neoplasms by application of biphasic electric pulses. J Exp Clin Cancer Res, 2003; 22(4):571–580.
111.
ChoiEW. Deep dermal and subcutaneous canine hemangiosarcoma in the perianal area: Diagnosis of perianal mass in a dog. BMC Vet Res, 2019; 15(1):115; doi: 10.1186/s12917-019-1852-6
112.
BrodzkiA, ŁopuszyńskiW, BrodzkiP, et al.Pharmacological treatment of perianal gland tumors in male dogs. Animals (Basel), 2023; 13(3):463; doi: 10.3390/ani13030463
113.
KellyJM, BeldingBA, SchaeferAK. Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin. Vet Comp Oncol, 2010; 8(2):81–86; doi: 10.1111/j.1476-5829.2010.00208.x
114.
ProbstU, FuhrmannI, BeyerL, et al.Electrochemotherapy as a new modality in interventional oncology: A review. Technol Cancer Res Treat, 2018; 17:1533033818785329; doi: 10.1177/1533033818785329
115.
MorettiG, DentiniA, BeccatiF, et al.Palliative repeated electroporations of oral tumours in dogs: A case series. Front Vet Sci, 2022; 9:1004811; doi: 10.3389/fvets.2022.1004811
116.
BorgognoniL, PescitelliL, GerliniG, et al.Efficacy of electrochemotherapy in the treatment of cutaneous melanoma metastases and rare non-melanoma skin cancer. Anticancer Res, 2020; 40(11):6485–6492; doi: 10.21873/anticanres.14670
117.
RibeiroRCS, AnjosDS, PazziniJM, et al.Evaluation of cell proliferation and apoptosis markers as predictive factors for electrochemotherapy in cutaneous squamous cell carcinoma of cats. Pesq Vet Bras, 2023; 43; doi: 10.1590/1678-5150-pvb-6518
118.
LoweR, GavazzaA, ImpellizeriJA, et al.The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision. Vet Comp Oncol, 2017; 15(3):775–784; doi: 10.1111/vco.12217
119.
VivodG, OmerzelM, KovacevicN, et al.Treatment of vulvar cancer recurrence with electrochemotherapy: A case-control study. Acta Oncol, 2024; 63:351–357; doi: 10.2340/1651-226X.2024.33241
120.
NguyenSM, ThammDH, VailDM, et al.Response evaluation criteria for solid tumours in dogs (v1.0): A veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol, 2015; 13(3):176–183; doi: 10.1111/vco.12032
121.
McMillanAT, McElroyL, O’TooleL, et al.Electrochemotherapy vs radiotherapy in the treatment of primary cutaneous malignancies or cutaneous metastases from primary solid organ malignancies: A systematic review and narrative synthesis. Cao H. PLoS One, 2023; 18(7):e0288251; doi: 10.1371/journal.pone.0288251
122.
FerioliM, PerroneAM, BuwengeM, et al.Combination of electrochemotherapy with radiotherapy: A comprehensive, systematic, PRISMA-Compliant review of efficacy and potential radiosensitizing effects in tumor control. Curr Oncol, 2023; 30(11):9895–9905; doi: 10.3390/curroncol30110719
123.
de SenaBV, TurqueteP, PimentelPAB, et al.Case report: Complete clinical remission of feline progressive histiocytosis after multimodal treatment including electrochemotherapy. Front Vet Sci, 2024; 11:1397592; doi: 10.3389/fvets.2024.1397592
124.
TreggiariE, CataniaE, PorcellatoI. Treatment with electrochemotherapy and tyrosine kinase inhibitors in a dog with an inoperable oral squamous cell carcinoma. Vet Oncol, 2025; 2(1):4; doi: 10.1186/s44356-025-00019-2
125.
TrotovsekB, HadzialjevicB, CemazarM, et al.Laparoscopic electrochemotherapy for the treatment of hepatocellular carcinoma: Technological advancement. Front Oncol, 2022; 12:996269; doi: 10.3389/fonc.2022.996269
126.
IzzoF, GranataV, FuscoR, et al.A multicenter randomized controlled prospective study to assess efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer. J Clin Med, 2021; 10(17):4011; doi: 10.3390/jcm10174011
127.
DjokicM, DezmanR, CemazarM, et al.Percutaneous image guided electrochemotherapy of hepatocellular carcinoma: Technological advancement. Radiol Oncol, 2020; 54(3):347–352; doi: 10.2478/raon-2020-0038
128.
SpugniniEP, MenicagliF, PettoraliM, et al.Ultrasound guided electrochemotherapy for the treatment of a clear cell thymoma in a cat. Open Vet J, 2017; 7(1):57–60; doi: 10.4314/ovj.v7i1.8
